Drug intelligence / Profile preview

human prothrombin complex (CSL Limited)

Development stage
Phase 4
Lead developer
CSL Behring
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Prothrombinex-VF is an Australian-produced, plasma-derived three-factor prothrombin complex concentrate (3F-PCC) manufactured by CSL Behring. It is derived from human plasma collected by Australian Red Cross Lifeblood and contains concentrated human coagulation factors II, IX, and X, along with low levels of antithrombin III and heparin sodium to reduce thrombotic risk. Prothrombinex-VF is indicated for the treatment and perioperative prophylaxis of bleeding in patients with acquired deficiency of prothrombin complex factors (such as those induced by vitamin K antagonists like warfarin) or congenital deficiencies of factors II, IX, or X when purified single-factor products are unavailable. It is administered intravenously as a reconstituted powder.

Brand names
Prothrombinex-VFProthrombinex
Other names
human prothrombin complexprothrombin complex concentrate3-factor prothrombin complex concentrate3F-PCCfactor IX complex
02

Targets

F2 (Thrombin)F9 (Coagulation Factor IX)F7 (Coagulation Factor VII)F10 (Factor Xa)

Beyond the preview

Go deeper on human prothrombin complex (CSL Limited).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human prothrombin complex (CSL Limited).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call